Moderna stock last at USD 199.29 in New York trading
Published on 09/25/2026 at 18:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna stock was last at USD 199.29 in New York trading at 12:44 p.m. ET on September 25, 2026, up USD 4.47 or 2.29 percent from the previous session reference. Bernstein's Market Perform reiteration and USD 45.00 target added a fresh analyst reference to the session. Moderna has scheduled Phase 3 melanoma data and an investor webcast for October 24, 2026.
The session on September 25, 2026 in figures
Moderna Inc. (ISIN US60770K1079, Nasdaq: MRNA) opened at USD 195.34 and reached an intraday high of USD 200.00. The shares then touched an intraday low of USD 192.51 before recovering to USD 199.29 at 12:44 p.m. ET. The session range measured USD 7.49 from high to low. Moderna's USD 200.00 high matched its 52-week high, while the 52-week low stood at USD 22.28.
Moderna traded 7,206,186 shares at 12:44 p.m. ET. The Nasdaq Composite stood at 27,088.28, up 148.91 points or 0.55 percent at 12:44 p.m. ET. Moderna's 2.29 percent advance exceeded the index move by 1.74 percentage points. The shares were USD 0.71 below the session high at that time.
Bernstein keeps a cautious rating after Moderna data progress
As The Crypto Basic reported on September 25, 2026, Bernstein reiterated its Market Perform rating and USD 45.00 price target. Bernstein analyst Courtney Breen said the next test was whether intismeran could show similar success across other indications and clinical settings. The USD 45.00 target stood USD 154.29 below Moderna's USD 199.29 trading price at 12:44 p.m. ET. The report identified the Phase 3 melanoma program as the basis for the assessment.
Moderna's September 21, 2026 release said Phase 3 intismeran autogene data had been selected for a Presidential Symposium at ESMO Congress 2026. As Moderna stated, the company will host an investor webcast on October 24 at 1:00 p.m. EDT. The presentation concerns adjuvant treatment data in patients with resected stage IIB-IV melanoma. The scheduled event keeps the cancer vaccine program as a dated reference for the shares.
Nasdaq, biotechnology peers and New York trading on September 25, 2026
The Nasdaq Composite was at 27,088.28, up 0.55 percent, at 12:44 p.m. ET. BioNTech shares traded at USD 99.40, up 0.14 percent, while Pfizer shares stood at USD 28.37, down 0.14 percent, at 12:44 p.m. ET. Moderna's gain was 2.15 percentage points above BioNTech's and 2.43 percentage points above Pfizer's. The broader technology index therefore showed a positive session backdrop alongside more restrained moves among the selected biotechnology peers.
Moderna's USD 199.29 price was USD 0.71 below its USD 200.00 session high at 12:44 p.m. ET. The USD 192.51 low was USD 6.78 below the latest price. The USD 7.49 intraday range represented 3.76 percent of the latest price. The Nasdaq Composite's 0.55 percent rise left Moderna ahead by 1.74 percentage points.
